ADVFN US – Market Content Editor
-
Acrivon Therapeutics shares slide sharply following mixed oncology trial update
Acrivon Therapeutics Inc (NASDAQ:ACRV) shares tumbled 29.2% on Thursday after the clinical-stage biotechnology company disclosed a mixed set of results from its ongoing cancer studies, which appeared to fall short of investor expectations. The company reported an overall response rate of 39% in its Phase 2b study evaluating ACR-368 as a monotherapy in OncoSignature-positive patients…
-
Ardelyx shares climb on robust 2025 sales and confident outlook for 2026
Ardelyx (NASDAQ:ARDX) shares jumped 15% on Thursday after the biopharmaceutical company released preliminary revenue figures for 2025 alongside a positive strategic outlook for the year ahead. The company reported total product revenue of roughly $378 million for 2025, marking an 18% increase year over year. Its flagship therapy, IBSRELA, delivered about $274 million in sales,…
-
Babcock & Wilcox shares jump on Siemens Energy deal tied to AI data center project
Shares of Babcock & Wilcox Enterprises Inc (NYSE:BW) surged 19.1% on Thursday after the company revealed a strategic partnership with Siemens Energy to supply steam turbine generator sets for a one-gigawatt power facility supporting an Applied Digital AI Factory. The agreement represents a key milestone in B&W’s previously outlined plan to engineer and deploy four…
-
U.S. Productivity surges while labor costs fall
The Labor Department reported on Thursday that U.S. labor productivity rose far more than forecast in the third quarter of 2025. Productivity jumped 4.9% during the quarter, following an upwardly revised 4.1% increase in the second quarter. Economists had expected a more modest gain of 3.6%, compared with the previously reported 3.3% rise. At the…
-
U.S. trade gap narrows sharply in October as exports rise and imports fall
New figures released by the Commerce Department on Thursday showed a surprise contraction in the U.S. trade deficit during October, defying expectations for a wider shortfall. According to the report, the trade gap narrowed to $29.4 billion in October, down from a downwardly revised $48.1 billion in September. Economists had anticipated the deficit would widen…
-
U.S. jobless claims tick higher in early January
New data from the U.S. Labor Department released on Thursday showed a modest rise in initial unemployment claims during the first week of January, coming in slightly below market expectations. According to the report, first-time claims for jobless benefits increased to 208,000 in the week ended January 3, up by 8,000 from the prior week’s…
-
Oil rebounds sharply after recent slide as U.S. stock draw offsets Venezuela uncertainty
Oil prices climbed strongly on Thursday, recovering from two consecutive declines after fresh data showed a larger-than-expected drop in U.S. crude inventories, even as developments around Venezuela continued to dominate market attention. By 07:50 ET (12:50 GMT), Brent crude futures for March delivery were up 1.6% at $60.93 per barrel, while U.S. West Texas Intermediate…
-
Dow Jones, S&P, Nasdaq, Wall Street futures signal a modestly weaker start
U.S. stock index futures are pointing to a slightly lower open on Thursday, suggesting equities may come under pressure after a mixed finish in the previous session. The softer tone follows comments from President Donald Trump calling for a sharp increase in U.S. military spending to $1.5 trillion by 2027. “This will allow us to…
-
Frontier confirms James Dempsey as CEO and lifts fourth-quarter profit expectations
Frontier Group Holdings Inc. (NASDAQ:ULCC) has named James G. Dempsey as its permanent president and chief executive officer, effective January 7, the airline said. Dempsey, who had been serving as interim CEO since December 2025, has also been appointed to the company’s board. Dempsey has spent more than ten years with Frontier. Board chairman Bill…
-
MoonLake shares surge after FDA outlines approval route for HS therapy
MoonLake Immunotherapeutics (NASDAQ:MLTX) jumped about 25% on Thursday after the company disclosed encouraging regulatory feedback from the U.S. Food and Drug Administration regarding Sonelokimab (SLK) for the treatment of Hidradenitis Suppurativa (HS). Following a Type B meeting, the FDA indicated that MoonLake may be able to demonstrate substantial evidence of effectiveness for SLK in HS…